Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib plus Paclitaxel in Recurrent Ovarian Cancer
NCT01091428Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Apr 2010
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alisertib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), breast cancer, sponsored by Millennium Pharmaceuticals. Started Apr 2010; status: completed.
02
Drugs
alisertib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)breast cancer
Beyond the preview
Go deeper on NCT01091428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01091428.